Exchange: NASDAQ·Updated 04:41 PM EDT

APMD Apnimed Inc.

$18.51
$1.92
(11.54%)
Today
Closed $18.51
$0.00
(0.00%)
After Hours
EarningsNov 11
Mkt Cap$690.86M
Vol310,998.00

About APMD

Apnimed, Inc. operates as a clinical-stage company. It engages in the discovery, development, and commercialization of oral therapies for sleep-related breathing diseases. The company was founded by Lawrence G. Miller, Barry Wohl and Luigi Taranto Montemurro in 2017 and is headquartered in Cambridge, MA.
37

Bearish Sentiment

How do you feel about APMD?

TraderGOAT
$APMD The market is giving you another chance to load the dip closer to the IPO price of $16. PDUFA on deck for February. Will most likely be at 50-60 prior. First pill form ever for sleep apnea patients currently using CPAP machines. Do your dd...
7
bsprelude
$APMD For all the neurological benefits for getting sleep apnea under control with a pill, I am very excited for APMD’s Oxnimbi. Price target avg of $50 seems justified… Bullish!
3
Merlintrader
📅 CATALYST REMINDER | $APMD October 20, 2026 — Clinical Data Presentation AD109 analyses from the Phase 3 SynAIRgy and LunAIRo programs will be presented at CHEST 2026. These are follow-up analyses, not a new pivotal readout. More details in our hub. #APMD #Biotech #CHEST2026
Cryptobearcat
$APMD New to this ticker. Did management ever hint what they would charge per month for AD 109?

Advertisement|Remove ads.